options investing


With a surprising last-minute surge, the Dow Jones Industrial Average and S&P 500 finished at record highs on Friday, extending the 11th straight session-ending record for the Dow. The Dow ended up 0.96% for the week with the S&P 500 not far behind with its own 0.69% gain. However, some companies made news this past week, so without further ado, here are some of the markets’ biggest moves and headlines.

Finally moving past scandal?

If you remember about a year ago, the Centers for Disease Control and Prevention let the world know that consumers who had purchased the China-produced flooring from Lumber Liquidators Holdings (NYSE:LL) were roughly three times more likely to fall ill with cancer. That rate was much higher than earlier calculations following the 2015 broadcast by CBS’ 60 Minutes.The stock shed much of its value since the 2015 airing, but rebounded 17% on Tuesday after it reported a narrower-than-expected loss during the fourth quarter, offering investors a slight amount of hope going forward.

options investing: Majesco Entertainment Company(COOL)


Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

options investing: Orexigen Therapeutics, Inc.(OREX)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios:

  • [By Cameron Saucier]

    Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company that aims to treat obesity. The company’s flagship drug, Contrave, is approved by the Food and Drug Administration (FDA) in the United States. The drug regulates appetite, energy use, and the central nervous system. OREX rose 63% last month after it announced a new commercial and distribution agreement with Biologix FZCO. The agreement will cover 10 countries in the Middle East. OREX is currently trading at $3.30 per share and is down 79% as of Jan. 9 year over year (YOY).

options investing: Liberty Interactive Corporation(QVCA)


Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    QVC (QVCA) was upgraded to buy from neutral at Bank of America/Merrill Lynch. $25 price target. The company can turn its sales around and deserves a higher multiple, analysts said. 

options investing: Sinovac Biotech Ltd.(SVA)

Advisors’ Opinion:

  • [By Monica Gerson]

    Sinovac Biotech Ltd. (NASDAQ: SVA) is expected to post its quarterly earnings.


    Supercom Ltd (NASDAQ: SPCB) is estimated to post its quarterly earnings at $0.15 per share on revenue of $9.03 million.

options investing: Finisar Corporation(FNSR)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Friday was a good day on Wall Street, as the stock market responded favorably to encouraging news on the employment front. The U.S. unemployment rate dropped on fairly strong job creation during the month of February, and that helped push the Dow, S&P 500, and Nasdaq Composite to modest gains of roughly between a quarter percent and a half percent. Yet even with a positive mood among market participants, some stocks weren’t able to participate in the end-of-week rally. Finisar (NASDAQ:FNSR), Zumiez (NASDAQ:ZUMZ), and Winnebago Industries (NYSE:WGO) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

  • [By Leo Sun]

    Shares of fiber optic components maker Finisar (NASDAQ:FNSR) fell 17% in April due to a big third-quarter miss in mid-March. Its revenue rose 23% annually to $380.6 million, but that missed expectations by $9 million. Earnings rose136% to $0.59 per share, but that also missed estimates by three cents. Finisar’s top and bottom line guidance for the fourth quarter (16% sales growth and 83% earnings growth at the midpoints) also came in below Wall Street estimates.

  • [By Dan Caplinger]

    The stock market had a negative tone on Wednesday, although major benchmarks moved in different directions. The Dow Jones Industrials took the biggest hit, falling triple digits as one of its most influential components suffered an earnings-related drop. Relative strength in the Nasdaq Composite showed cross-currents in the overall market, but several individual stocks had substantial declines for the day, andRite Aid (NYSE:RAD), Diana Shipping (NYSE:DSX), and Finisar (NASDAQ:FNSR) were among the worst performers. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

options investing: Pilgrim's Pride Corporation(PPC)


Advisors’ Opinion:

  • [By John Udovich]

    Thanksgiving is almost here but the exit of both Pilgrim’s Pride Corporation (NYSE: PPC) and Smithfield Foods (NYSE: SFD) to focus on their chicken or pork businesses (the latter was also acquired by the Chinese) leaves just two big Thanksgiving turkey stocks, Hormel Foods Corporation (NYSE: HRL) and Seaboard Corporation (NYSEAMEX: SEB), for investors to consider. According to the American Far Bureau, a 16-pound turkey will (on average) come in at a total of $22.74 this year or roughly $1.42 per pound for a decrease of 2 cents per pound or a total of 30 cents per whole turkey, compared to 2015. The price drop may be a transition back to the norm as the significant bird flu outbreak last year hurt the nations supply of both turkey and eggs.

  • [By Peter Graham]

    The Q4 2016earnings report for mid cap chicken producer Pilgrim’s Pride Corporation (NASDAQ: PPC) scheduled for before the market opens on Thursday(February 9th). Pilgrim’s Pride Corporationis the sixth most shorted stock on the Nasdaq with short interest of 41.76%according to Highshortinterest.com. Theelevated short interest comes in the wake of the worstbird-flu outbreak in the US whichhad hurt demand and triggered import bans abroad.

Leave a Reply

Your email address will not be published. Required fields are marked *